ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer

被引：0
|
作者：
Subudhi, S. K. [1 ]
Wise, D. [2 ]
Liu, S. T. [3 ]
Chaudhry, A. [4 ]
Kim, J. [5 ]
Gardner, O. [6 ]
Gilbert, H. [6 ]
Grady, M. [6 ]
Paoloni, M. [6 ]
Krishnan, K. [6 ]
Carducci, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] NYU Langone Hlth, Med, New York, NY USA
[3] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[4] Summit Canc Ctr, Med Oncol, Spokane, WA USA
[5] Yale Univ, Med Oncol, New Haven, CT USA
[6] Arcus Biosci, Clin Dept, Hayward, CA USA
[7] Johns Hopkins, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687TiP
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [21] Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer
    Armstrong, A. J.
    Gingrich, J. R.
    Haggman, M.
    Stadler, W. M.
    Damber, J. E.
    Belkoff, L.
    Clark, R.
    Brosman, S.
    Nordle, O.
    Forsberg, G.
    Carducci, M. A.
    Pili, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E126 - U515
  • [22] Phase Ib/II open-label study to evaluate the safety, tolerability, and efficacy of rivoceranib plus trifluridine/tipiracil in patients with previously treated metastatic colorectal cancer
    Eng, C.
    Park, C. H.
    Meng, X.
    Jang, S. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S453 - S454
  • [23] Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study
    Li, Jin
    Liu, Jihong
    Yin, Rutie
    Zou, Dongling
    Zheng, Hong
    Cao, Junning
    Chen, Zhendong
    Sun, Wei
    Gao, Yunong
    Zhang, Songling
    Zeng, Linjuan
    An, Ruifang
    Lu, Xianping
    Ye, Shuang
    Wu, Xiaohua
    MOLECULAR CANCER, 2024, 23 (01)
  • [24] An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer
    Garcia-Carbonero, Rocio
    Rivera, Fernando
    Maurel, Joan
    Ayoub, Jean-Pierre M.
    Moore, Malcolm J.
    Cervantes, Andres
    Asmis, Timothy R.
    Schwartz, Jonathan D.
    Nasroulah, Federico
    Ballal, Shaila
    Tabernero, Josep
    ONCOLOGIST, 2014, 19 (04): : 350 - 351
  • [25] A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pill, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
    Reni, Michele
    Dugnani, Erica
    Cereda, Stefano
    Belli, Carmen
    Balzano, Gianpaolo
    Nicoletti, Roberto
    Liberati, Daniela
    Pasquale, Valentina
    Scavini, Marina
    Maggiora, Paola
    Sordi, Valeria
    Lampasona, Vito
    Ceraulo, Domenica
    Di Terlizzi, Gaetano
    Doglioni, Claudio
    Falconi, Massimo
    Piemonti, Lorenzo
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1076 - 1085
  • [27] Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study
    Dreicer, R.
    Agus, D. B.
    MacVicar, G. R.
    Wang, J.
    MacLean, D.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
    Shore, Neal D.
    Efstathiou, Eleni
    Patel, Rupal
    Xu, Rongda
    Johnson, Ann
    Multani, Pratik S.
    Morris, Michael J.
    Abida, Wassim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: An open-label, phase II dose-confirmation study
    Savulsky, C.
    Twelves, C.
    Anthoney, A.
    Yin, S.
    Evans, T. R. J.
    Oncology Research and Treatment, 2015, 38 : 253 - 253
  • [30] Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study
    Twelves, Chris
    Nasim, Muhammad Y.
    Anthoney, Alan
    Savulsky, Claudio I.
    Yin, Shuxin
    Evans, T. R. Jeffry
    CANCER RESEARCH, 2015, 75
12345